SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) Fundamental Analysis & Valuation

FRA:PSH0 • CA81752F1062

0.0805 EUR
-0.01 (-10.06%)
Last: Mar 3, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This PSH0.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

Overall PSH0 gets a fundamental rating of 0 out of 10. We evaluated PSH0 against 75 industry peers in the Biotechnology industry. Both the profitability and financial health of PSH0 have multiple concerns. PSH0 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. PSH0.DE Profitability Analysis

1.1 Basic Checks

  • In the past year PSH0 has reported negative net income.
  • In the past year PSH0 has reported a negative cash flow from operations.
  • PSH0 had negative earnings in each of the past 5 years.
  • PSH0 had a negative operating cash flow in each of the past 5 years.
PSH0.DE Yearly Net Income VS EBIT VS OCF VS FCFPSH0.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • PSH0 has a Return On Assets of -2060.13%. This is amonst the worse of the industry: PSH0 underperforms 96.00% of its industry peers.
Industry RankSector Rank
ROA -2060.13%
ROE N/A
ROIC N/A
ROA(3y)-888.07%
ROA(5y)-546.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSH0.DE Yearly ROA, ROE, ROICPSH0.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • PSH0 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSH0.DE Yearly Profit, Operating, Gross MarginsPSH0.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PSH0.DE Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for PSH0 has been increased compared to 1 year ago.
  • PSH0 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PSH0 has a worse debt to assets ratio.
PSH0.DE Yearly Shares OutstandingPSH0.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
PSH0.DE Yearly Total Debt VS Total AssetsPSH0.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • PSH0 has an Altman-Z score of -405.30. This is a bad value and indicates that PSH0 is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -405.30, PSH0 is not doing good in the industry: 92.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -405.3
ROIC/WACCN/A
WACCN/A
PSH0.DE Yearly LT Debt VS Equity VS FCFPSH0.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.02 indicates that PSH0 may have some problems paying its short term obligations.
  • With a Current ratio value of 0.02, PSH0 is not doing good in the industry: 96.00% of the companies in the same industry are doing better.
  • PSH0 has a Quick Ratio of 0.02. This is a bad value and indicates that PSH0 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.02, PSH0 is doing worse than 96.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
PSH0.DE Yearly Current Assets VS Current LiabilitesPSH0.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PSH0.DE Growth Analysis

3.1 Past

  • PSH0 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.77%, which is quite impressive.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PSH0 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.07% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.61%
EPS Next 2Y17.59%
EPS Next 3Y14.34%
EPS Next 5Y27.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PSH0.DE Yearly Revenue VS EstimatesPSH0.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
PSH0.DE Yearly EPS VS EstimatesPSH0.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. PSH0.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PSH0. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSH0. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSH0.DE Price Earnings VS Forward Price EarningsPSH0.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSH0.DE Per share dataPSH0.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.01 -0.02 -0.03 -0.04 -0.05

4.3 Compensation for Growth

  • PSH0's earnings are expected to grow with 14.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.59%
EPS Next 3Y14.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PSH0.DE Dividend Analysis

5.1 Amount

  • No dividends for PSH0!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PSH0.DE Fundamentals: All Metrics, Ratios and Statistics

SERNOVA BIOTHERAPEUTICS INC

FRA:PSH0 (3/3/2026, 7:00:00 PM)

0.0805

-0.01 (-10.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-19
Earnings (Next)N/A
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners4.07%
Ins Owner ChangeN/A
Market Cap27.10M
Revenue(TTM)N/A
Net Income(TTM)-15.74M
Analysts80
Price Target2.27 (2719.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.74%
Min EPS beat(2)0.99%
Max EPS beat(2)50.5%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.38%
PT rev (3m)6.98%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)28.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)50%
Revenue NY rev (3m)50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2060.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-888.07%
ROA(5y)-546.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -405.3
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y4.61%
EPS Next 2Y17.59%
EPS Next 3Y14.34%
EPS Next 5Y27.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y52.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.69%
EBIT Next 3Y23.38%
EBIT Next 5Y40.68%
FCF growth 1Y42.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.27%
OCF growth 3YN/A
OCF growth 5YN/A

SERNOVA BIOTHERAPEUTICS INC / PSH0.DE FAQ

Can you provide the ChartMill fundamental rating for SERNOVA BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to PSH0.DE.


What is the valuation status of SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to SERNOVA BIOTHERAPEUTICS INC (PSH0.DE). This can be considered as Overvalued.


Can you provide the profitability details for SERNOVA BIOTHERAPEUTICS INC?

SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) has a profitability rating of 0 / 10.